Mesoblast data positive, says Maxim Maxim believes that Mesoblast reported positive topline efficacy results from a Phase 2 trial of MPCs in patients with type 2 diabetes. The firm says the data sounds "really good," but adds that it's early to draw conclusions. It thinks the recent pullback in the stock is unjustified and keeps a Buy rating on the shares.
News For MBLTY From The Last 14 Days
Check below for free stories on MBLTY the last two weeks.